


Name SURNAME: Carlos A. M. Afonso			
Function:	Full Professor (Role in the project: Coordinator)		
Institution:	Faculty of Pharmacy, University of Lisbon Av. Prof. Gama Pinto 1649-003 Lisboa Portugal		<input type="checkbox"/> Funding Agency <input type="checkbox"/> Programme Manager
Email:	carlosafonso@ff.ulisboa.pt		
Phone:	+351 217 946 400 (Ext. 14614; office); + 351 933111611 (mobile)		
Division	Research Institute for Medicines (iMed.Ulisboa)		
Areas of Expertise:			
Organic chemistry, new catalyzed synthetic methodologies with special emphasize on the catalyst reuse namely by immobilizing in ionic liquids, water and PEGs, synthetic valorisation of biorenewable resources and creation and application of new ionic liquids.			
Short Description of your Institution:			
iMed.Ulisboa (http://www.imed.ulisboa.pt) is a multidisciplinary R&D Unit in Life and Health Sciences supported by FCT, and hosted at Faculty of Pharmacy, ULisboa (FF/ULisboa; http://www.ff.ul.pt/). The Principal Contractor of iMed.Ulisboa is represented by FARM-ID, a private not-for-profit association of FF/ULisboa for R&D, which aims to provide efficient administrative and management support, consolidation of back office operations, and optimal use of resources, thus enabling iMed.Ulisboa to continue focusing on its core research activities. iMed.Ulisboa mission is to develop innovative medicines and benefit human health through top-class multidisciplinary research. Capabilities are built around a network of 15 research groups, spanning the drug discovery and development spectrum, with an emphasis on innovative, multidisciplinary, and collaborative research. FF/ULisboa provides administrative support, office and laboratory space, access to infrastructures, human resources and technical support.			
Role in the project:			
Coordinator. Besides the involvement in the WP1, 5&6, Afonso will be dedicated to the execution of WP4 namely the implementation of efficient organic synthetic transformation of the products from lupanine bioconversion to valuable target molecules and the transformation of isolated lupanine to sparteine and other analogues.			

August 10, 2016